Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207277 | 0.81 | CHRM2 (0.43) | POLBCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL9136497 | 0.79 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL3317821 | 0.78 | CHRM2 (0.39) | POLBCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13398561 | 0.74 | OPRM1 (0.38) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL668021 | 0.74 | HCAR2 (0.40) | LMNACHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL668521 | 0.74 | HCAR2 (0.40) | LMNACHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL592258 | 0.74 | OPRM1 (0.40) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL9048771 | 0.73 | CHRM2 (0.43) | CHRM2CHRM4CHRM1CHRM3 | |
| Bromide SCHEMBL6628170 | 0.73 | OPRM1 (0.39) | CHRM2CHRM4CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL8558853 | 0.71 | CHRM2 (0.39) | CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557819-B2 | Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics | SANOFI (FR) | 2013-10-15 | — | — | US | disclosed |
| US-8557819-B2 | Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics | SANOFI (FR) | 2013-10-15 | — | — | US | disclosed |
| US-8557819-B2 | Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics | SANOFI (FR) | 2013-10-15 | — | — | US | disclosed |
| US-20120046298-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2012-02-23 | — | — | US | disclosed |
| US-20120046298-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2012-02-23 | — | — | US | disclosed |
| US-20120046298-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2012-02-23 | — | — | US | disclosed |
| US-8076340-B2 | Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| US-8076340-B2 | Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| US-8076340-B2 | Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20090088440-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| US-20090088440-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| US-20090088440-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-04-02 | — | — | US | disclosed |
| US-7476674-B2 | Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2009-01-13 | — | — | US | disclosed |
| US-7476674-B2 | Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2009-01-13 | — | — | US | disclosed |
| US-7476674-B2 | Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics | SANOFI-AVENTIS (FR) | 2009-01-13 | — | — | US | disclosed |
| US-20080176855-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176855-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176855-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088440-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | TPMT, DHFR, S1PR5 | TSHR 1210/4885LMNA 2469/4885POLB 696/4885 |
| US-20080176855-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | TPMT, DHFR, S1PR5 | TSHR 1210/4885LMNA 2469/4885POLB 696/4885 |
| US-20120046298-A1 | DERIVATIVES OF 5-PYRIDAZINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | TPMT, DHFR, S1PR5 | TSHR 1210/4885LMNA 2469/4885POLB 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.